Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks
暂无分享,去创建一个
Manel Sabaté | Salvatore Brugaletta | S. Brugaletta | M. Sabaté | L. Ortega‐Paz | G. Giacchi | Kohki Ishida | Giuseppe Giacchi | Luis Ortega-Paz | Kohki Ishida
[1] J. Wykrzykowska,et al. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users , 2015, Netherlands Heart Journal.
[2] V. Kocka,et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’ , 2014, European heart journal.
[3] Z. Siudak,et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry. , 2014, Kardiologia polska.
[4] Patrick W Serruys,et al. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? , 2012, European heart journal.
[5] J. Tijssen,et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[6] P. Serruys,et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary ste , 2015, JACC. Cardiovascular interventions.
[7] Sunil V. Rao,et al. Randomized trial of primary PCI with or without routine manual thrombectomy. , 2015, The New England journal of medicine.
[8] P. Serruys,et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. , 2014, European heart journal.
[9] J. Ormiston,et al. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[10] D. Fernández-Rodríguez,et al. Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent? , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[11] T. Münzel,et al. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes. , 2015, JACC. Cardiovascular interventions.
[12] P. Serruys,et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.
[13] S. Brugaletta,et al. ST-segment elevation myocardial infarction – ideal scenario for bioresorbable vascular scaffold implantation? , 2015, Circulation journal : official journal of the Japanese Circulation Society.
[14] Seung‐Jung Park,et al. Late Stent Malapposition After Drug-Eluting Stent Implantation: An Intravascular Ultrasound Analysis With Long-Term Follow-Up , 2006, Circulation.
[15] E. Edelman,et al. Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings , 2011, Circulation.
[16] Elias Sanidas,et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. , 2014, JACC. Cardiovascular interventions.
[17] J. Brachmann,et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[18] G. Stone,et al. How to minimize stent thrombosis. , 2011, Circulation.
[19] Chi‐Hang Lee,et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[20] R. Whitbourn,et al. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[21] M. Bennett,et al. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[22] Z. Siudak,et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. , 2014, Polskie Archiwum Medycyny Wewnetrznej.
[23] M. Togni,et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. , 2015, Journal of the American College of Cardiology.
[24] Helmut Baumgartner,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[25] M. Valgimigli,et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. , 2015, Journal of the American College of Cardiology.
[26] J. Jąkała,et al. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes. , 2015, Cardiology journal.
[27] C. Hamm,et al. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. , 2014, Journal of the American College of Cardiology.
[28] Antonio Colombo,et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[29] S. Achenbach,et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold , 2014, Clinical Research in Cardiology.
[30] Seung‐Jung Park,et al. Incidence, Mechanism, Predictors, and Long-Term Prognosis of Late Stent Malapposition After Bare-Metal Stent Implantation , 2004, Circulation.
[31] R. Virmani,et al. Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model , 2014, Circulation. Cardiovascular interventions.
[32] Patrick W Serruys,et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? , 2012, European heart journal.
[33] Bernard Chevalier,et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? , 2012, Atherosclerosis.
[34] S. Achenbach,et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[35] M. Valgimigli. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY , 2011 .
[36] C. Di Mario,et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. , 2014, JACC. Cardiovascular interventions.
[37] Gijs van Soest,et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. , 2014, Journal of the American College of Cardiology.
[38] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.
[39] T. Münzel,et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[40] A. Ielasi,et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry). , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.